Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/5069| Title: | Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview |
| Issue Date: | 30-May-2013 |
| Publisher: | Dove Press |
| Description: | William B Hillegass1, Brigitta C Brott2, James C Dobbs2, Silvio E Papapietro2, Vijay K Misra2, Gilbert J Zoghbi21Columbiana Cardiovascular Consultants, Columbiana, AL, USA; 2Interventional Cardiovascular Section, University of Alabama at Birmingham, AL, USAAbstract: Diabetics have a prothrombotic state that includes increased platelet reactivity. This contributes to the less favorable clinical outcomes observed in diabetics experiencing acute coronary syndromes as well as stable coronary artery disease. Many diabetics are relatively resistant to or have insufficient response to several antithrombotic agents. In the setting of percutaneous coronary intervention, hyporesponsiveness to clopidogrel is particularly common among diabetics. Several strategies have been examined to further enhance the benefits of oral antiplatelet therapy in diabetics. These include increasing the dose of clopidogrel, triple antiplatelet therapy with cilostazol, and new agents such as prasugrel. The large TRITON TIMI 38 randomized trial compared clopidogrel to prasugrel in the setting of percutaneous coronary intervention for acute coronary syndromes. The diabetic subgroup (n = 3146) experienced considerable incremental benefit with a 4.8% reduction in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke at 15-month follow-up with prasugrel treatment. Among diabetics on insulin this combined endpoint was reduced by 7.9% at 15 months. Major bleeding was not increased in the diabetic subgroup. This confirms the general hypothesis that more potent oral antiplatelet therapy can partially overcome the prothrombotic milieu and safely improve important clinical outcomes in diabetics.Keywords: percutaneous coronary intervention, acute coronary syndromes, diabetes mellitus, prasugrel, antithrombotic agents |
| URI: | http://koha.mediu.edu.my:8181/jspui/handle/123456789/5069 |
| Other Identifiers: | http://www.dovepress.com/oral-antiplatelet-therapy-in-diabetes-mellitus-and-the-role-of-prasugr-a7885 http://www.doaj.org/doaj?func=openurl&genre=article&issn=11766344&date=2011&volume=2011&issue=default&spage=445 |
| Appears in Collections: | Health Sciences |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.